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Genetic variants of endothelial nitric oxide synthase (eNOS) could influence individual susceptibility to 
coronary artery disease (CAD) with or without associated demographic factors. The aim of this study 
was to assess whether Glu
298
/Asp polymorphism of the eNOS gene is associated with the occurrence 
and severity of angiographycially defined coronary artery disease. Polymerase chain 
reaction/restriction fragment length polymorphism (PCR-RFLP) analyses were carried out to detect the 
Glu
298
/Asp variant of the eNOS gene in 279 patients with CAD as compared to controls (250). The 
prevalence of the Asp
298
 variant of eNOS was not found to be significantly and independently 
associated with the risk of CAD (OR = 1.08, 95% CI = 0.77 to 1.51, P = 0.663), extent of CAD on 
angiography (OR = 1.18, 95% CI = 0.63 to 2.23, P = 0.605) and in-hospital mortality (OR = 1.08, 95% CI = 
0.29 to 4.04, P = 0.908). This investigation examined whether the Glu
298
/Asp polymorphism of the eNOS 
could represent a useful genetic marker to identify individuals prone to the development of 
atherosclerotic diseases. More studies are needed to confirm whether the Glu
298
/Asp polymorphism of 
the eNOS gene could represent a useful genetic marker to identify individuals of the study population 
prone to the development of atherosclerotic disease. 
 





Coronary atherosclerosis is a common disease that 
causes ischemic heart diseases, such as angina pectoris 
and myocardial infarction. Many patients have no 
symptom, despite the presence of coronary artery 
disease (CAD). They may have silent ischemia or are 
unaware of potentially dangerous abnormal heart 
rhythms (arrhythmias). The absence of chest pain or 
other common symptoms can also set the stage for a 
heart attack that occurs without warning. Hence, it is 
important to look at biomarkers for early detection of 
CAD. Coronary risk factors, such as hypertension, 
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cause this disorder. Recently, the gene polymorphisms of 
angiotensin-converting enzyme (ACE)1 and 
apolipoprotein eNOS gene have been reported as 
independent risk factors for myocardial infarction, 
although the genetic cause of this disorder has not been 
proved completely. Epidemiological studies also indicate 
that hyperlipidmeia, hypertension, cigarette smoking, 
diabetes and obesity are risk factors for coronary artery 
disease. These environmental risk factors have, however, 
been ineffective and completely predicting development 
of the atherosclerotic process, suggesting that specific 
genetic predisposition should be taken into account as 
well. Vascular endothelium modulates blood vessel wall 
homeostasis through the production of factors regulating 
vessel tone coagulation state, cell growth, cell death and 





endothelial cell products is nitric oxide (NO), which is 
synthesized from L-arginine by the enzyme endothelial 
nitric oxide synthase (eNOS). Endothelial nitric oxide 
synthase (eNOS; NOS3) produces nitric oxide (NO) from 
L-arginine. NO has diverse physiologic regulatory 
functions and is involved in smooth muscle relaxation, 
inhibition of platelet aggregation, immune regulation, 
neurotransmission and blood pressure regulation 
(Moncada and Higgs, 1993; Schimidt and Walter, 1994; 
Forte et al., 1994). Moreover, it has been shown that 
eNOS inhibition accelerates atherosclerosis in animal 
models, and that abnormalities of the endothelial NO 
pathway is present in humans with atherosclerosis. This 
evidence suggests that NO may inhibit several key steps 
in the atherosclerotic process and that an alteration of 
NO production within the vascular endothelium could 
contribute to the pathogenesis of atherosclerosis. Thus 
eNOS could be a candidate gene for atherosclerosis. 
A single base exchange (G
894
→T) in exon 7 of the 
human endothelial nitric oxide synthase (eNOS) gene 
results in a Glu→Asp substitution at residue 298 of the 
eNOS gene. The functional significance of this single 
nucleotide polymorphism remains an issue of controversy 
since homozygosity for the Asp
298
 variant has been 
related to reduced enzyme activity (Veldman et al., 2002) 
and basal NO production (Wang et al., 2000), possibly 
due to increased susceptibility to proteolytic cleavage, 
although more recent reports have convincingly 
demonstrated that this preferential cleavage could be a 
methodological artefact (Tesauro et al., 2000; Fairchild et 
al., 2001; Mc Donald et al., 2004). 
In accordance with the hypothesis that this 
polymorphism may have an unfavorable effect on NO 
bioavailability, homozygosity for the Asp
298
 variant has 
been shown to influence vascular coronary reactivity as 
reported by Chang et al. (2001), responsiveness to a-
adrenergic stimulation and event free survival in patients 
with nonischemic cardiomyopathy ( Philip et a., 1999; 
McNamara et a., 2003). Based on these reports, a 
number of association studies have positively associated 
the presence of the Asp
298
 variant with risk of acute 
myocardial infarction (AMI) (Hingorani et al., 1999; 
Antoniades et al., 2005), carotid atherosclerosis (Lembo 
et al., 2001), early atherogenesis and coronary in-stent 
restenosis (Paradossi et al., 2004; Gomma et al., 2002) 
while several studies have found no evidence for an 
association between the Glu
298
→Asp polymorphism and 
premature CAD (Granath et al., 2001; Yamada et al., 
2002; Spence et al., 2004; Zhang et al., 2006). 
Several polymorphisms have been identified in the 
eNOS gene, among which is one located in exon 7 
(G894T) which modifies its coding sequence (Glu
298
/Asp). 
Associations between this variant and coronary spasm, 
coronary artery disease and acute myocardial infarction 
have been reported, but data on its relation with disease 
severity are lacking. In this paper, we examined the 
associations between theGlu
298
/Asp polymorphism of the 
eNOS gene and the occurrence of  angiographically  defined  








MATERIALS AND METHODS 
 
Selection criteria  
 
We included 279 patients with angiographically diagnosed CAD, 
consecutively admitted to our institution with angiographically 
proven coronary artery disease (more than 50% stenosis affecting 
at least one vessel) and 250 healthy controls, in whom 
angiographic examination excluded the presence of coronary artery 
disease. The controls were those who came to the hospital with 
pain in the chest but did not have a history of angina pectoris or 





All the cases and age matched healthy controls were interviewed 
and epidemiological data/demographic data on smoking habits, 
hypertension, diabetes dyslipidaemia and family history of coronary 
artery disease were recorded. Informed consent was obtained from 
all the patients and the healthy controls, as required by our Hospital 
ethics committee.  
 
 
Data on risk factors 
 
For CAD risk factors, the following were used: subjects were 
defined as hypertensive if their blood pressure was >140/90 mmHg 
or if they were receiving any antihypertensive treatment; those with 
a history of diabetes or who were receiving any antidiabetic drug 
were considered to be diabetic; those with a total plasma 
cholesterol concentration of >200 mgs/dl or a triglyceride 
concentration of >180 mgs/dl, or who were receiving lipid lowering 
drugs, were considered dyslipidmic. Smoking history was recorded 
as either none or current smokers. A positive family history was the 
presence of a first degree relative with coronary artery disease at 





All patients underwent coronary angiography. Coronary stenosis 
was considered significant in the presence of a luminal diameter 
narrowing of >50% of at least one pericardial coronary artery. The 
severity of coronary artery disease was expressed by the number of 
affected vessels (one, two, or three vessel disease) and also by 
means of the Duke scoring system13: a prognostic index that 
includes the number of diseased major vessels, the presence of left 
main coronary artery disease, the percentage of narrowing of the 
major vessels, and involvement of the left anterior descending 
coronary artery, particularly when the proximal segment shows 
severe stenosis (>95%). The Duke score ranges from 0 to 100 (0 = 





Blood samples were collected from all the subjects after 12 h 
fasting and placed in EDTA tubes and stored at -80°C until the time 
of assay: for DNA extraction and for biochemical assays. The 
serum concentrations of triglyceride (TG), total cholesterol, LDL 
cholesterol (LDL-C) and HDL cholesterol (HDL-C), urea, createnine 
and random blood sugar (separate blood sample was  collected  for  






Figure 1. Restriction fragment polymorphism of eNOS gene: Bi-
allelic polymorphism in exon 7 of the eNOS 3 gene detected by 
MboI restriction endonuclease digestion of the 139-bp PCR 
product. Lanes 1 and 2, restriction digested samples showing 
restriction patterns corresponding to heterozygocity for Asp/Glu; 
Lanes 3 and 7, restricted digested samples showing restriction 
patterns corresponding to homozygosity for Asp
298 
; Lanes 4, 6 and 
8, samples subjected to restriction digestion samples showing 









doing random blood sugar) were measured by the standard 
methods (Auto-analyzer) used in the clinical laboratory of the 





/Asp polymorphism for exon 7 of eNOS 
gene 
 
Genomic DNA was extracted from samples of whole blood by 
standard methods (Shi et al., 2008) .The coding sequence variant 
was a G→T substitution at position 894 in exon 7 which determines 
the Glu to Asp amino acid substitution (in codon 298) in the mature 
eNOS protein. According to previously described procedure 
(Munshi et al., 2010), genotyping of all the subjects was performed 
by polymerase chain reaction amplification of exon 7 with the 
primers 5’-CATGAGGCTCAGCCCCAGAAC -3’(sense) and 5’-
AGTCAATCCCTTTGGTGCTCAC -3’(antisense) followed by MboI 
restriction enzyme digestion for 16 h at 37°C. In the presence of a T 
at nucleotide 894 which corresponds to Asp
298
, the139 base pair 
(bp) polymerase chain reaction product was cleaved into two 
fragments of 119 and 20 bp. The products of the digestion process 





Genotype distributions in the cases and controls were examined for
 
significant deviation (P < 0.05) from Hardy-Weinberg equilibrium. 
The frequencies of risk-associated
 
variants were compared in the 
cases and controls by using the χ
2
 test (SPSS 13.0 Chicago). Allelic 
frequencies were calculated according to the number of different 
alleles observed and the total number of alleles examined. The 
differences between groups were examined by 
2
 test. The 
frequencies of the alleles and genotypes were compared between 
the patient and control groups by the χ
2
. We performed multivariate 
logistic regression analysis to adjust risk factors, in which CAD was 
a dependent variable and independent variables were 
hypertension, smoking, diabetes, TG, total cholesterol level, LDL-C, 










The main baseline characteristics of the patients with 
CAD (cases) and of the subjects from the general 
population (controls) are presented in Table 1. The 
frequencies of the studied genotypes of the eNOS gene 
are shown in Table 2. The observed frequencies of the 
studied alleles were in Hardy-Weinberg equilibrium in 
both the cases (χ
2 
= 0.20, P > 0.1) and controls (χ
2 
= 
1.65, P > 0.1). 
The frequency of the Asp/Asp genotype was not found 
to differ significantly between the cases and controls in 
relation to the major coronary risk factors (gender, 
smoking status, diabetes mellitus, hypercholesterolemia, 
hypertension, obesity and family history of CAD). 
Furthermore, the average number of the earlier 
mentioned risk factors did not differ significantly in the 
carriers versus non-carriers of the Asp/Asp genotype, in 
both cases (2.36 vs. 2.32, P = 0.771) and controls (1.60 
vs. 1.81, P = 0.137). 
The frequency of the mutated genotype (Asp/Asp) did 
not differ significantly between cases and controls (11.2 
vs. 10.7%, P = NS). Similarly, the Glu/Asp (43.8 vs. 40.9, 
P = NS) and the Glu/Glu (45.1 vs. 48.4, P = NS) 
genotypes did not differ significantly between the study 
groups in the univariate analysis. In backward stepwise 
logistic regression analysis with age, gender, smoking 
status, diabetes mellitus, hypercholesterolemia, 
hypertension, obesity and family history of CAD included 
as covariates, the presence of the Asp/Asp genotype was 
not found to be independently associated with CAD (OR 
= 1.08, 95% CI = 0.77–1.51, P = 0.663) (Figure 2). 
The frequencies of the Asp/Asp genotype in relation to 
the number of diseased vessels were 13.3, 8.1, and 9.3% 
in patients with one-, two- and three-vessel disease, 
respectively (P = 0.192). In multivariate analysis adjusted 
for age, gender, diabetes mellitus, smoking status, 
hypertension, hypercholesterolemia and obesity, the 
Asp/Asp variant was not found to be independently 
associated with the number of diseased vessels on 
coronary angiography (OR = 1.18, 95% CI = 0.63 to 2.23, 





The eNOS gene has a number of polymorphic sites, 
including SNPs, di-nucleotide repeats and variable 
number tandem repeat sequences, and the opportunity 
exists to investigate polymorphic functional correlation as 
well as disease-specific associations, especially in 
cardiovascular disease, including coronary artery 
disease, and its most severe consequence, myocardial 
infarction. Several polymorphisms have been identified in  




Table 1. Baseline characteristics of the study population. 
 
Parameter Case (n = 280) Control (n = 250) P value 
Age (years) 62 ± 13 58 ± 15 < 0.001 
Male gender 78.9% (221) 42.8% (107) < 0.001 
Diabetes 28.9% (81) 10.8% (27) < 0.001 
Cigarette smoking 63.9% (179) 34% (82) < 0.001 
Hypercholesterolaemia 50% (140) 34% (82) < 0.001 
Hypertension 45% (126) 32% (80) < 0.001 




Table 2. Allele frequencies of the Glu
298 
—›Asp polymorphism 
in CAD patients and controls. 
 
Parameter Glu (%) Asp (%) 
Patients 60.02 37.97 






Figure 2. Synopsis of the results of genotype analyses. The 
distributions of genotypes in relation to the disease are shown (data 
shown in %). Detailed description of the variables included in each 





the eNOS gene, among which is one located in exon 7 
(G894T) which modifies its coding sequence (Glu
298 
/Asp). 
A case-control study evaluating the potential 
association between Glu
298
→Asp eNOS polymorphism 
and the risk of CAD reached the conclusion that 
homozygosity for eNOS Asp
298
 allele was associated with 
a moderately, though significantly increased risk of CAD 
(OR = 1.31;95% CI  =  1.13–1.51)  (Casas  et  al.,  2004).  
The reported results are amenable to criticism due to the 
significant heterogeneity of the individual odds ratios 
incorporated in the calculation of the summary odds ratio. 
After extracting the most influential odds ratio from the 
analysis of the study, the authors abrogated the 
methodological limitation of heterogeneity, but the 
calculated risk of CAD was largely blunted and bordered 
on significance (OR = 1.17; 95% CI = 1.00–1.36; P = 
0.05). 
Antoniades et al. (2005) in an elegantly designed study 
with 229 consecutive patients with premature CAD 
demonstrated that homozygosity for this polymorphism is 
associated with a significantly increased risk for 
premature CAD. Although discordant at a first glance with 
our results, the conclusions of this study refer to a 
different, younger than our patient population, where the 
relative contribution of the Glu
298
→Asp polymorphism to 
the susceptibility for CAD might be enhanced. A large 
scale study on 5061 individuals of Japanese origin 
demonstrated no association of the Glu
298
→Asp 
polymorphism with the risk of CAD (Yamada et al., 2002; 
Spence et al., 2004), using family-based association tests 
specifically designed for the study of the genetic basis of 
multifactorial diseases. There was no evidence that the 
Glu
298
→Asp eNOS gene polymorphism was related to the 
development of CAD in a total of 1023 Caucasian 
individuals. 
In a recent study of 861 diabetic men, no significant 
association was observed between Glu
298
→Asp eNOS 
polymorphism and risk of CAD (Zhang et al., 2006). 
There is also discrepancy in the literature regarding the 
association between the Glu
298
→Asp polymorphism and 
premature CAD. Granath and colleagues (Granatha et 
al., 2001) studying 573 patients younger than 50 years 
reported the absence of the association between 
Glu
298
→Asp eNOS polymorphism and premature CAD, 
while in a recent smaller trial, the TT genotype was 
significantly and independently associated with 
premature CAD (Cam et al., 2005; Gardemann et al., 
2002) under the studied young individuals with high risk 
of atherosclerotic profile and they reported an association 
between Glu
298
→Asp eNOS polymorphism and CAD in 
this cohort. To our knowledge, this study is the first speci-
fically designed study conducted in a Saudi poplation to 
test the  possible  association  of  this polymorphism  with 




risk of CAD. Our results have not validated the 
association between G
894
→T polymorphism, in the eNOS 
gene and increased risk of CAD. 
Identifying a correlation among genes and risk for 
coronary heart disease is a first step in a long path to 
potentially important clinical implications. What we are 
looking for, ultimately, are novel therapeutics and/or life-
style modifications that can be recommended to 
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